Literature DB >> 26886135

Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

Sean G Kelly1, Amesika N Nyaku1, Babafemi O Taiwo2,3.   

Abstract

The advent of combination antiretroviral therapy (ART) has significantly decreased AIDS-related morbidity and mortality. Nevertheless, the benefits of ART are only realized through adherence to lifelong treatment. Though contemporary antiretroviral (ARV) drugs have fewer adverse effects in comparison to older ARV drugs, many agents are associated with negative or unknown long-term effects. There is increasing evidence that two-drug (dual-therapy) regimens may be an effective alternative to the currently recommended three-drug (triple-therapy) regimens. In this review, we provide a comprehensive and critical review of recently completed and ongoing trials of dual-therapy regimens in treatment-naïve and treatment-experienced HIV-1-infected patients. We also review current HIV/AIDS society recommendations regarding dual therapy as well as future therapeutic possibilities.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26886135     DOI： 10.1007/s40265-016-0553-8

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  30 in total

1.  Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.

Authors:  Juan Berenguer; Antonio Rivero; Antonio Javier Blasco; José Ramón Arribas; Vicente Boix; Bonaventura Clotet; Pere Domingo; Juan González-García; Hernando Knobel; Pablo Lázaro; Juan Carlos López; Josep M Llibre; Fernando Lozano; José M Miró; Daniel Podzamczer; Montserrat Tuset; Josep M Gatell
Journal:  Enferm Infecc Microbiol Clin       Date:  2015-08-28       Impact factor: 1.731

2.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

Authors:  Zabrina L Brumme; James Goodrich; Howard B Mayer; Chanson J Brumme; Bethany M Henrick; Brian Wynhoven; Jerome J Asselin; Peter K Cheung; Robert S Hogg; Julio S G Montaner; P Richard Harrigan
Journal:  J Infect Dis       Date:  2005-06-23       Impact factor: 5.226

3.  Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.

Authors:  Polyana Monteiro; Iñaki Perez; Montserrat Laguno; Maria Martínez-Rebollar; Ana González-Cordon; Montserrat Lonca; Josep Mallolas; Jose L Blanco; Jose M Gatell; Esteban Martínez
Journal:  J Antimicrob Chemother       Date:  2013-10-14       Impact factor: 5.790

4.  Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.

Authors:  Nadia Ahmed; Chinyere Okoli; Jonathan Ainsworth
Journal:  Int J STD AIDS       Date:  2015-05-11       Impact factor: 1.359

5.  Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.

Authors:  Pedro Cahn; Jaime Andrade-Villanueva; José R Arribas; José M Gatell; Javier R Lama; Michael Norton; Patricia Patterson; Juan Sierra Madero; Omar Sued; Maria Inés Figueroa; Maria José Rolon
Journal:  Lancet Infect Dis       Date:  2014-04-27       Impact factor: 25.071

6.  Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

Authors:  Clotilde Allavena; Virginie Ferré; Cécile Brunet-François; Jean-François Delfraissy; Alain Lafeuillade; Marc-Antoine Valantin; Michelle Bentata; Christian Michelet; Isabelle Poizot-Martin; Eric Dailly; Odile Launay; François Raffi
Journal:  J Acquir Immune Defic Syndr       Date:  2005-07-01       Impact factor: 3.731

7.  The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.

Authors:  Michael P Girouard; Paul E Sax; Robert A Parker; Babafemi Taiwo; Kenneth A Freedberg; Roy M Gulick; Milton C Weinstein; A David Paltiel; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

8.  Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

Authors:  M A Boyd; N Kumarasamy; C L Moore; C Nwizu; M H Losso; L Mohapi; A Martin; S Kerr; A H Sohn; H Teppler; O Van de Steen; J-M Molina; S Emery; D A Cooper
Journal:  Lancet       Date:  2013-06-15       Impact factor: 79.321

9.  Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.

Authors:  Mauro Zaccarelli; Massimiliano Fabbiani; Carmela Pinnetti; Vanni Borghi; Alberto Giannetti; Gaetana Sterrantino; Patrizia Lorenzini; Alessandra Latini; Laura Loiacono; Manuela Colafigli; Adriana Ammassari; Gabriella D'Ettorre; Maddalena Plazzi; Simona Di Giambenedetto; Andrea Antinori
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

10.  Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Authors:  Nicholas I Paton; Cissy Kityo; Anne Hoppe; Andrew Reid; Andrew Kambugu; Abbas Lugemwa; Joep J van Oosterhout; Mary Kiconco; Abraham Siika; Raymond Mwebaze; Mary Abwola; George Abongomera; Aggrey Mweemba; Hillary Alima; Dickens Atwongyeire; Rose Nyirenda; Justine Boles; Jennifer Thompson; Dinah Tumukunde; Ennie Chidziva; Ivan Mambule; Jose R Arribas; Philippa J Easterbrook; James Hakim; A Sarah Walker; Peter Mugyenyi
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245
View more
  5 in total

1.  GSK3732394: a Multi-specific Inhibitor of HIV Entry.

Authors:  David Wensel; Yongnian Sun; Jonathan Davis; Zhufang Li; Sharon Zhang; Thomas McDonagh; David Langley; Tracy Mitchell; Sebastien Tabruyn; Patrick Nef; Mark Cockett; Mark Krystal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

2.  Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.

Authors:  Jean van Wyk; Mounir Ait-Khaled; Jesus Santos; Stefan Scholten; Michael Wohlfeiler; Faïza Ajana; Bryn Jones; Maria-Claudia Nascimento; Allan R Tenorio; Don E Smith; Jonathan Wright; Brian Wynne
Journal:  J Acquir Immune Defic Syndr       Date:  2021-06-01       Impact factor: 3.771

3.  Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.

Authors:  Lisi Deng; Chunna Li; Ping Chen; Xiaoqing Luo; Xinchun Zheng; Lanlan Zhou; Yi Zhou; Jinyu Xia; Zhongsi Hong
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

4.  Advancements in nano-enabled therapeutics for neuroHIV management.

Authors:  Ajeet Kaushik; Rahul Dev Jayant; Madhavan Nair
Journal:  Int J Nanomedicine       Date:  2016-09-01

5.  Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.

Authors:  Jean van Wyk; Faïza Ajana; Fiona Bisshop; Stéphane De Wit; Olayemi Osiyemi; Joaquín Portilla Sogorb; Jean-Pierre Routy; Christoph Wyen; Mounir Ait-Khaled; Maria Claudia Nascimento; Keith A Pappa; Ruolan Wang; Jonathan Wright; Allan R Tenorio; Brian Wynne; Michael Aboud; Martin J Gartland; Kimberly Y Smith
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.